| INTRODUCTION
Anal squamous cell carcinoma (ASCC) is a rare tumor, but its incidence has been increasing over the past 2 decades. [1] [2] [3] This cancer is closely related to human papillomavirus (HPV) infection. 4 Most patients are diagnosed with locally advanced disease, for which the standard of care is chemoradiotherapy (CRT). 5 High complete response rates are obtained, but 20% of patients are nonresponders or relapse within the first 3 years after treatment. Salvage abdominoperineal resection (APR) is the standard treatment for local failure or recurrence after CRT, but 30% to 60% of operated patients subsequently experience locoregional and/or metastatic recurrence. 6, 7 Very few treatments with very limited efficacy are available for these patients with inoperable locally advanced or metastatic disease. A better understanding of the molecular markers involved in anal carcinogenesis is necessary in order to identify new therapeutic targets as well as prognostic and predictive biomarkers. In comparison with other squamous cell carcinomas and HPV-related cancers, the molecular landscape of ASCC is currently not well characterized and few genomic studies are available. [8] [9] [10] Only limited and old data are available concerning the recurrent pattern of chromosomal aberrations in ASCC. 11, 12 Only one study was based on a comparative genomic hybridization (CGH) approach, but concerned a cohort of 35 cases of anal intra-epithelial neoplasia. 13 In this study, we present the results of array-CGH analysis of 49 ASCC patients with comparison of genomic profiles between treatment-naive tumors and recurrences.
| MATERIALS AND METHODS

| Sample collection
Forty-nine tumor samples from 49 patients with ASCC (ie, no paired samples from same patients) treated between 1992 and 2015 at the Institut Curie Hospital were retrospectively analyzed. All biopsy tissues were residual specimens and macrodissected to achieve maximum tumor purity. A fresh frozen tumor sample was considered suitable for the study when the proportion of tumor cells exceeded 70%. This retrospective study was reviewed and approved by the Institut Curie Ethics Committee (No. A10-024). According to French regulations, patients were informed about the research performed on the biological specimens obtained during their treatment and did not express any opposition. Clinical and laboratory data were collected for each patient. Disease staging was based on the 7th revised edition (2010) of the American Joint Committee on Cancer (AJCC) staging of anus cancer. Fifteen samples of adjacent normal anal squamous cell tissue from patients with ASCC were used as sources of normal RNA for RT-qPCR. Tissues samples were stored at −70°C until DNA and RNA extractions.
| Genomic DNA extraction
The Qiagen DNeasy Tissue kit and the protocols for fresh frozen ASCC tissues were used. DNA was purified by column purification with a filter membrane and stored at −20°C before use.
| Total RNA extraction
Total RNA was extracted from fresh frozen ASCC and normal anal squamous cell tissues by the acid-phenol guanidium method. The quantity of RNA was assessed using an ND-1000 NanoDrop Spectrophotometer with its corresponding software (Thermo Fisher Scientific Inc., Wilmington, DE). RNA quality was determined by electrophoresis on agarose gel with ethidium bromide staining. The 18S and 28S RNA bands were visualized under ultraviolet light. Total RNA was stored at −20°C before use.
deletions were observed for 5 loci (ie, TGFR2 in 4 cases), and recurrent focal amplifications were observed for 8 loci (ie, DDR2 and CCND1 in 3 cases, respectively).
| HPV genotyping
HPV status was assessed in the Institut Curie Pathology Department. Total DNA, isolated from formalin-fixed tissue blocks, was used for HPV typing. Real-time PCR using Sybr ® Green and specific primers for HPV16 and 18 was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA).
| Mutation assessment
HRM primers for screening mutations were designed for KRAS (exons 2, 3, and 4), BRAF (exon 15), PIK3CA (exons 9 and 20), and TP53 (exons [5] [6] [7] [8] . PCR for HRM analysis was performed on a 384-well plate in the presence of the fluorescent DNA intercalating dye, LC green (Idaho Technology) in a LightCycler480 ® (Roche). HRM analysis was performed with Genescan software (Roche). All samples were plotted according to their melting profiles on the differential plot graph. All samples were sequenced using Sanger sequencing approach, whenever an abnormal HRM curve was suspected.
The nucleotide sequences of the oligonucleotide primers for the genes examined are listed in Table S1 .
| Array-CGH
ASCCs were tested using a 400K human genome CGH microarray. Array-CGH experiments were carried out using standard Agilent protocols (Agilent Technologies, Santa Clara, CA). Commercial human genomic DNA (Agilent Technologies) was used as diploid reference. Briefly, 1-1.5 μg of reference DNA and the same amounts of patient tumor DNA were digested with Alu1 and Rsa1 (Promega, Madison, WI, USA). The digested reference DNA fragments were labeled with cyanine 3-dUTP, and tumor DNA was labeled with cyanine 5-dUTP (Agilent Technologies). After cleanup, labeled reference and tumor DNA were mixed as probes and hybridized onto an Agilent 400K human genome CGH microarray (Agilent Technologies) for 40 hours. Washing, scanning, and data extraction procedures were carried out according to standard protocols. Data were extracted using Feature Extraction software (v11.1), and normalized data were analyzed and visualized by Agilent Cytogenomics Edition 2.9.2.4 (Agilent Technologies). The aberration detection module 2 (ADM-2) with threshold 6 was used to calculate copy number alterations (CNAs). Five-probe 0.20_log2 filter was used for aberration evaluation, given an average genomic resolution of 7 Kb. DGV database (hg19) was used for elimination of the common copy number polymorphism regions from the dataset. Cytogenomics Edition 2.9.2.4 (Agilent Technologies) was used to calculate the log2 ratio for each probe and to identify genomic aberrations. The mean log2 ratio of all probes in a chromosome region between 0.20 and 1.0 was classified as genomic gain, more than 1.0 (with a size <10 Mb) as focal amplification, less than −0.30 as heterozygous deletion, and less than −1.0 (with a size <5 Mb) as homozygous deletion.
| RT-qPCR
The theoretical and practical aspects of RT-qPCR have been previously described in detail. 14 The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (ie, lack of extensive degradation) are both difficult to assess. Transcripts of an endogenous RNA control gene involved in cellular metabolic pathway, namely TBP (Genbank accession NM_003194), 15 which encodes the TATA box-binding protein (a component of the DNA-binding protein complex TFIID), were therefore also quantified. Each sample was normalized on the basis of its TBP content. Results, expressed as N-fold differences in target gene expression relative to the TBP gene and termed "Ntarget," were determined as Ntarget = 2
ΔCtsample
, where the ΔCt value of the sample was determined by subtracting the Ct value of the target gene from the Ct value of the TBP gene. The Ntarget values of the samples were subsequently normalized so that the median of the 15 normal anal squamous cell tissue Ntarget values was 1. cDNA synthesis and PCR conditions were as previously described.
14 Primers for TBP and the target genes were designed with the assistance of Oligo 6.0 software (National Biosciences, Plymouth, MN).
To avoid amplification of contaminating genomic DNA, 1 of the 2 primers was placed at the junction between 2 exons or on between 2 different exons. Agarose gel electrophoresis was used to verify the specificity of PCR amplicons. The nucleotide sequences of the oligonucleotide primers for the selected genes are listed in Table S2 .
| Statistical analysis
Correlations between molecular parameters (at the RNA or/ and DNA level), and clinical, biological, and pathological parameters, were identified using nonparametric tests, namely Chi-square or Fisher's exact test (correlation between 2 qualitative parameters), and Kruskal-Wallis test (correlation between 1 qualitative parameter and 1 quantitative parameter). OS was defined as the interval from the first day of RT or CRT to death from any cause. In order to assess the efficacy of a molecular marker (number of altered regions and fraction of genome altered) to discriminate between 2 populations (alive/deceased patients) in the absence of an arbitrary cutoff value, data were summarized in a ROC (receiver operating characteristic) curve. 16 The area under curve (AUC) was calculated as a single measure to discriminate efficacy. Survival distributions were estimated by the Kaplan-Meier method, and the significance of differences between survival
rates was ascertained with the log-rank test. For all statistical tests, differences were considered significant at P < .05.
| RESULTS
| Patient and tumor characteristics
A total of 49 ASCC samples from 49 patients treated in our institution were included and analyzed for CNA and KRAS, BRAF, PIK3CA, and TP53 mutations. Tumor characteristics in the total population according to the treatment-naive or recurrence status of the samples are summarized in Table  S3 . Twenty-seven tumors were treatment-naive and 22 were samples from recurrence after initial RT or CRT. A total of 46 tumors (93.9%) were HPV-positive, including 43 tumors (87.5%) with HPV16 infection. Only 4 patients (8.2%) had HIV infection, and all presented concomitant HPV infection. The study population comprised 38 females and 11 males. Eight patients were treated by first-line surgery: exclusive surgery (n = 4) and surgery followed by RT (n = 3) or CRT (n = 1). Twelve patients were treated by first-line RT and 29 by first-line CRT. The median follow-up of the 49 patients was 46.2 months (range: 9.8 to 278 months). Eight of the 27 treatment-naive patients relapsed after the initial diagnosis.
| Whole-genome array-CGH profiles
Array-CGH profiles of the 49 ASCCs are represented in Figure 1A . Gains and deletion metrics for each sample are listed in Table S4 . The first genomic parameter corresponds to the number of distinct identified CGH segments reflecting the number of break points within the tumor genome. This parameter ranged from 68 to 550, with a median of 137. The second genomic parameter corresponds to the fraction (percentage) of the altered genome. This parameter ranged from 0.96% to 51.94%, with a median of 17.82%.
| Heterozygous and homozygous deletions
The most significantly frequent minimal regions of heterozygous deletion with a frequency greater than 25% were located at loci 2q35 (27%), 2q36.3 (29%), 3p21.2 (39%), 4p16.3 (29%), 4p31.21 (27%), 7q36.1 (27%), 8p23.3 (41%), 10q23.2 (27%), 11q22.3 (55%), and 13q14.11 (22%) ( Table 1A ; Figure 1A ). The most common frequent minimal region of heterozygous deletion in 55% of ASCCs encompassed the 8.4-Mb region containing ATM ( Figure S1 ). Other common regions of heterozygous genomic deletion containing well-known tumor suppressor genes were located at 3p21.2 (BAP1, PBRM1, and FHIT), 10q23.2 (PTEN, that also showed 2 homozygous deletions; Figure S2 ), and 13q14.11 (RB1) ( Table 1A) . Expression of ATM and PTEN located in 2 of the smallest common CNAs of interest was then screened for 41 of the 49 ASCC using RT-qPCR to assess correlations between copy number alterations and mRNA expressions in ASCC tumors. ATM and PTEN were significantly underexpressed in ASCCs with heterozygous/homozygous deletions, compared to diploid tumors (P = .006 and P = .02, respectively; Figures S1 and S2). Fifty-four homozygous deletions were identified, including 5 recurrent homozygous deletions for the loci: LRP1B (2q21.2; n = 2), TGFBR2 (3p22; n = 4), PTEN (10q23.3; n = 2), TRAF3 (14q32.32; n = 2), and MACROD2 (20p12.1; n = 3) ( Table 2A) 
| Genomic gain and focal amplification
The most significantly frequent minimal regions of gain with a frequency greater than 25% were located at loci 1p36.33 (37%), 1q21.1 (29%), 3q26.32 (57%), 5p15.33 (29%), 8q24.3 (39%), 9q34.3 (33%), 16p13.3 (41%), and 19p13.3 (27%) (Table 1B; Figure 1A ). The most common frequent minimal region of gain in 57% of ASCCs encompassed the 3q26.32 region containing PIK3CA and TERC ( Figure S3 ). PIK3CA (but not TERC) mRNA was significantly overexpressed in the ASCCs with 3q26.32 gains, compared to diploid tumors (P = .013; Figure S3 ), suggesting that PIK3CA is the likely target of this gain event in this chromosomal region. Other common regions of genomic gain containing known oncogenes were located at 9q34.3 (NOTCH1) and 19p13.3 (FGFR2) ( Table 1B) . Sixty-three focal amplifications were identified, including 8 recurrent focal amplifications for the loci: DDR2 (1q23.3; n = 3), SFRP1 and NKX6-3 (8p11.21; n = 2), MYC (8q24.21; n = 2), CCND1 (11q13; n = 3), MAPRE2 (18q12.1; n = 2), NFIX, LYL1 (19p13.2; n = 2), AKT2 (19q13.2; n = 2), and DYRK1A and KCNJ6 (21q22.13; n = 2). It is noteworthy that 7 of the amplified genes in focal amplifications (ie, DDR2, CDK6, MET, IGF2, MDM2, FLT3, and AKT2) are targets for specific therapies (Table 2B ).
| Comparative genomic analysis of treatment-naive and recurrent tumor samples
As described in the literature, accumulation of gains/amplification and/or loss in the genome can generate a pattern of chromosomal alterations, which could specifically contribute to cancer progression. Based on these elements, we investigated whether such patterns of chromosomal abnormalities could be preferentially observed in the 22 recurrent tumors compared to the 27 treatment-naive tumors. The global load of genomic alterations was similar (Table S4) . Several individual genomic alterations ( Figure 1B ,C) were more frequently (but not statistically significantly) observed in the recurrent tumor group compared to the treatmentnaive tumor group including, for example, heterozygous deletions at 2q35 (36% vs 19%) or gains at 5p15.33 (36% vs 22%) (Table 1A,B) . More surprisingly, several individual genomic alterations were statistically more frequently observed in the treatment-naive tumor group as compared to the recurrence tumor group, in particular heterozygous deletions at 11q14.2 (48% vs 9%; P = .003) or gains at 19q13.42 (33% vs 5%; P = .03) (Table 1A,1B). It is noteworthy that the 11q14.2 deleted region contains the well-known tumor suppressor gene EED that also shows a homozygous deletion (Table 2A) . T4  19q  37533808  39695155  2161  -53   T3  19q  37553808  39307259  1753  -40   T4  19q  44423396  44803072  379  -15   T11  19q  43884667  46295324  2411  -89   T11  19q  58419791  59082951  663  -33   T11  21q  20872889  23530026  2657  -2   T21  21q  29671040  31528208  1857  -12   T45  21q  32496947  37246707  4749  -16   T45  21q  37818180  39354904 
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( Table 3 ). The most frequently altered pathway in the 49 tumors was the PI3K/Akt/mTOR pathway, which was altered in 22 of the 49 tumors (44.9%). PI3K/Akt/mTOR pathway alterations included activating mutations of PIK3CA, homozygous deletion of PTEN, and focal amplifications of IGF2 and AKT2, and all of these somatic events were mutually exclusive. Interestingly, the PI3K/ Akt/mTOR pathway was altered significantly more frequently in recurrences than in treatment-naive tumors (64% vs 30%; P = .017) ( Table 3 ). It is noteworthy that the RAS/MAPK signaling pathway was rarely altered (2 of the 49 tumors; 4.1%).
| Correlation between genomic indices and clinicopathological features and prognostic value
As this retrospective cohort of 49 ASCC patients comprised tumor samples with heterogeneous sites and treatment status, the study population was divided into 2 groups of patients (treatment-naive tumors and recurrences) to study the association between the 2 genomic indices (number of distinct CGH segments identified and fraction of genome altered) and the patients' clinicopathological characteristics, and the impact of these 2 indices on OS.
The first group of treatment-naive tumors from 27 ASCC patients treated by first-line exclusive RT/CRT (Table  S3 ) had a median follow-up of 44.6 months (range: 13.9-169 months). The overall recurrence rate was 29.6% (n = 8 of 27). No correlation was observed between the 2 genomic indices and OS (data not shown).
The second group of 22 recurrent tumor samples (20 anal recurrences treated by APR and 2 metastases) from patients with ASCC who experienced recurrence after first-line RT or CRT (Table S3 ) had a median follow-up of 46.7 months (range: 9.8-278 months). The overall mortality rate after recurrence was 63.4% (n = 14 of 22).
Long-rank test demonstrated a significant correlation between poor OS and a large number of distinct CGH segments in recurrent tumors (P = .024) ( Figure 3A) , and a trend toward significance for a high fraction of the genome altered in treatment-naive tumors (P = .16) ( Figure 3B ). No correlation was observed between the number of distinct CGH segments and clinicopathological characteristics in the group of 22 recurrent tumors (Table S5 ) or in the group of 29 treatmentnaive tumors (data not shown).
| DISCUSSION
ASCC is considered to be a highly radiosensitive tumor, but 20% of patients fail to respond to CRT. No predictive markers of response to radiation-based therapy have been prospectively validated. Moreover, in patients who develop recurrence, APR is the treatment of choice, but no prognostic factors have been identified and no adjuvant therapy has been recommended. More accurate genomic characterization of anal carcinogenesis is crucial to improve the medical care of patients with ASCC by identifying new therapeutic targets or prognostic biomarkers. In this context, we conducted a large array comparative genomic hybridization analysis in treatment-naive and recurrent ASCC.
F I G U R E 2 TGFBR2 homozygous deletions
Despite previous exposure to ionizing radiation and DNA-damaging cytotoxic chemotherapy, the global load of genomic alterations was high but similar between treatmentnaive tumors and recurrences, in line with the mutational burden described in whole-exome analysis of ASCC 17 and in other types of carcinoma. 18, 19 Surprisingly, several individual genomic alterations were observed more frequently in the group of treatment-naive tumors. A significant correlation was demonstrated between genomic index and OS in the group of recurrent tumors (not observed in the group of treatment-naive tumors), with a high number of distinct CGH segments associated with poor prognosis. Due to the little size of our cohort, this correlation needs to be confirmed in a larger prospective randomized study.
Several recurrent minimal heterozygous deleted regions were identified in this study. It is noted that our methodology (CGH microarray but not SNP array) did not allow to estimate copy number neutral loss of heterozygosity (LOH). The most common frequent minimal region of deletion encompassed the 11q22.3 region, containing ATM. Five recurrent homozygous deletions were identified in the TGFBR2 (8%), MACROD2 (6%), PTEN (4%), LRP1B (4%), and TRAF3 (4%) loci. Homozygous deletions of TGFBR2, LRP1B, and TRAF3 genes have never been previously reported in ASCC. The TGFBR2 gene is involved in homeostasis of many tissues via the TGFβ signaling pathway. It encodes a tyrosine kinase receptor that is involved in cell proliferation, epithelialmesenchymal transition, and apoptosis. Bi-allelic inactivation of TGFBR2 using a keratin 14 promoter in mice leads to spontaneous genital and anal SCC. 20 Homozygous deletion of TGFBR2 has been reported in gastric and pancreatic cancer, 21, 22 and alteration of TGFBR2 expression is associated with poor prognosis in several cancers. 23, 24 The LRP1B gene encodes a member of the LDL receptor family of lipoprotein receptors that is involved in cholesterol metabolism and T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 T14 T15 T16 T17 T18 T19 T20 T21 T22 T23 T24 T25 T26 T27 Total % T28 T29 T30 T31 T32 T33 T34 T35 T36 T37 T38 T39 T40 T41 T42 T43 T44 T45 T46 T47 T48 T49 Total %  HPV  4 atherosclerotic lesion formation. Homozygous deletion of LRP1B has been reported in multiple malignancies, namely esophageal cancer, glioblastoma, and cervical cancer. [25] [26] [27] LRP1B gene has been recently identified as the integration site for HPV in cervical and oropharyngeal cancers. 27, 28 The TRAF3 gene encodes a cytoplasmic adaptor protein, with E3 ligase activity, which is involved in the signaling of a variety of adaptive and innate immune receptors as well as cytokine receptors. In particular, homozygous deletions of the TRAF3 gene have been detected in hematopoietic malignancies, such as multiple myeloma, non-Hodgkin lymphoma, and Bcell chronic lymphocytic leukemia. 29, 30 TRAF3 has recently been shown to be downregulated by HPV via upregulation of UCHL1 with suppression of the innate immune response in keratinocytes. 31 Several recurrent minimal regions of gain were identified. The most common frequent minimal region of gain, observed in 66% of ASCCs, encompassed the 3q26.32 region containing PIK3CA and TERC. Moreover, the RNA results identified PIK3CA (and not TERC) as the driver gene of this 3q26.32 region of gain. The PI3K/Akt/mTOR pathway has been often identified in previous ASCC sequencing studies with PIK3CA mutations in 20% to 30% of ASCC. 32, 33 Other common regions of genomic gain that contain known oncogenes, with potential therapeutic interest, were located at 9q34.3 (NOTCH1) and 19p13.3 (FGFR2). Several recurrent focal amplifications of known oncogenes with possible therapeutic implications were also identified: AKT2 (8%), DDR2 (6%), and IGF2 (4%), which are known to be targets for specific therapies and which could be used as novel agents in the treatment of ASCC. The AKT2 gene is a partner of the PI3K/Akt/mTOR pathway and is known to be amplified in HPV-associated squamous cell cancers. 34 Four of the other focal amplifications (ie, CDK6, MET, MDM2, and FLT3) are also targets for specific therapies. Considering the high prevalence of HPV infection in ASCC (approximately 95%) and its well-established role in the first steps of anal carcinogenesis, it seems difficult to distinguish signaling pathway changes caused by genetic mutations from those caused by HPV. However, TP53 mutations have been reported more frequently in the rare HPV-negative cases of ASCC 10, 33, 35, 36 and could therefore be involved in another pathway of anal carcinogenesis.
In conclusion, this study represents the largest array comparative genomic hybridization analysis in treatment-naive and recurrent ASCC. The results of this study further our knowledge of the genetic landscape of ASCC and highlight the crucial role of biological and molecular characterization of rare diseases for the development of new treatments. This study identifies new tumor suppressor genes, LRP1B and TRAF3, with possible interactions with HPV and confirmed the role of TGFBR2 and PTEN in ASCC carcinogenesis. We confirm the major role of activation of the PI3K/Akt/mTOR pathway in ASCC carcinogenesis (45% of tumors samples) as previously described, 32, 33 and in particular in recurrences, in which activation of this pathway was present in 66% of tumor samples. We also suggest several druggable target genes of this signaling pathway, such as IGF2, PIK3CA, and AKT2. Clinical studies based on prospective cohorts of patients with ASCC need to be conducted in order to demonstrate the antitumor efficacy of new targeting agents in light of the molecular alterations identified in the present study.
